Employment & Pensions

1. Please describe whether there is any legal regulation (laws or collective bargaining agreements) or other measures in this jurisdiction which prohibit sexual harassment in the workplace, and since...

A CMS team led by Alain Raemy (Corporate/M&A) has provided comprehensive legal advice to the Belgian Ecostal Group on the acquisition of Solex­is. Solex­is is a leading Swiss B2B provider of photovoltaic systems and solu­tions.  Eco­st­al Group is a growing player in the European solar market. The acquisition of Solexis is an integral part of Ecostal Group's expansion strategy aiming to grow through targeted acquisitions in strategic markets. CMS SwitzerlandAlain Raemy, Partner, Corporate / M&AAnna Mast, Associate, Corporate / M&AAlexander Salamon, Attorney Trainee, Corporate / M&AMark Cagienard, Partner, TaxJonas Weber, Associate, TaxDr Dirk Spacek, Partner, IP/ITMiryam Meile, Senior Associate, EmploymentJulia Nitschke, Associate, IP/IT

Zurich, July 2024 | An international CMS team under the lead of Stefan Brunnschweiler and Florian Jung provided comprehensive advice to Ypsomed (SIX: YPSN) on all legal aspects regarding the completion of the sale of its pen needle and blood glucose monitoring systems (BGMs) businesses to Medical Technology and Devices S.p.A. (MTD) across 17 jurisdictions. The sale of the pen needle and BGM businesses between Ypsomed and MTD was announced on 27 March 2024. The transaction is now legally completed after all conditions set out in the agreement have been fulfilled. During a transition phase, Ypsomed will continue to produce pen needles as a contract manufacturer and provide services to enable a seamless transfer. The production facilities will be gradually relocated to the MTD sites by mid-2025. The space freed up will be used for a new toolmaking facility at the Solothurn site. Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company will celebrate its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals as well as under Ypsomed Delivery Systems in busi­ness-to-busi­ness operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries, and distribution partners. Ypsomed has over 2,200 employees worldwide. CMS ZurichStefan Brunnschweiler, LL.M., Managing Partner, Head Corporate/M&AFlorian Jung, LL.M., Senior Associate, Corporate/M&ASamuel Felix Gang, LL.M., Senior Associate, Corporate/M&AAnna Mast, Associate, Corporate/M&AMaximilian Hochreiter, Attorney Trainee, Corporate/M&AAlexander Salamon, Attorney Trainee, Corporate/M&AMarquard Christen, LL.M., MAS, Partner, Com­pet­i­tion­Sophia Rovelli, Attorney Trainee, Com­pet­i­tion­Nad­ine Anwander, Attorney Trainee, CompetitionDr Matthias Kuert, LL.M., Partner, Capital MarketsMark Cagienard, LL.M. VAT, Partner, TaxChristian Gersbach, LL.M., Partner, EmploymentDirk Spacek, LL.M., Partner, IT/IPCMS ParisAlexandra Rohmert, Partner, Corporate/M&AVincent Desbenoit, Associate, Corporate/M&ACaroline Froger-Michon, Partner, Em­ploy­ment­Ca­mille Baumgarten, Associate, Em­ploy­ment­Aliénor Fevre, Counsel, CommercialManon Fleury, Associate, Com­mer­cialJean-Hugues de la Berge, Partner, TaxWilliam Hamon, Partner, TaxCMS FrankfurtDr Heike Wagner, Partner, Corporate/M&ADr Tobias Kilian, Of Counsel, Corporate/M&ADr Reiner Thieme, Associate, Corporate/M&ACMS HamburgDr Roland Wiring, Partner, IPCMS RomePietro Cavasola, Managing Partner, Corporate/M&ASerena Carroli, Counsel, Corporate/M&ACMS StavangerEspen Debes, Partner, Corporate/M&APreben Øvsthun-Sand­vik, Corporate/M&ACMS OsloJohan Svedberg, Partner, Corporate/M&ACMS BrusselsArnaud Van Oekel, Partner, Corporate/M&ALola Verelst, Associate, Corporate/M&ACMS MadridLuis Miguel de Dios, Partner, Corporate/M&AElena Alcazar, Counsel, Corporate/M&ACMS ViennaDieter Zandler, Partner, Com­pet­i­tion­Flori­an Mayer, Partner, Corporate/M&ACMS AmsterdamRoman Tarlavski, Partner, Corporate/M&AMaarten Feenstra, Associate, Corporate/M&ACMS LondonTom Jameson, Partner, Corporate/M&A CMS PragueHelen Rodwell, Partner, Corporate/M&AMonika Hospudkova, Associate, Corporate/M&ACMS StockholmRobert Kullgren, Partner, Corporate/M&AMinterEllison (Australia)Con Boulougouris, Partner, Corporate/M&AAlex Beagley, Senior Associate, Corporate/M&AWill Crammond, Associate, Corporate/M&AMoalem Weitemeyer (Denmark)Jakob Skafte-Pedersen, Partner, Corporate/M&AMichael Thai Hansen, Senior Associate, Corporate/M&AHPP Attorney (Finland)Björn Nykvist, Partner, Corporate/M&AAndrew Cotton, Partner, Corporate/M&AJoska Rytkönen, Senior Associate, Corporate/M&ABorder Ladner Gervais (Canada)David Henry, Partner, Corporate/M&AHSA Legal (India)Soumya De Mallik, Partner, Corporate/M&APrithviraj Chauhan, Principal Associate, Corporate/M&AMeghna Rajesh, Associate, Corporate/M&A

Zürcher Kantonalbank acquires Complementa AG. Complementa AG has been supporting Zürcher Kantonalbank (ZKB) with investment reporting services since 2006 and has become an important partner of the bank. ZKB has taken over Complementa as of July 26, 2024. The bank is thus consolidating its important position in the area of custody services. At the same time, the takeover provides Complementa with a viable, long-term succession solution. This step ensures the smooth continuation of the often long-standing client relationships. For Complementa's clients and employees, this solution represents continuity and stability. Heinz B. Rothacher will relinquish his role as CEO, but will continue to be represented on the Board of Directors. From September 2024, Markus Wirth, currently Head of Custody at ZKB, will become CEO of Complementa. He will continue to manage the company together with the existing management team. A team of CMS led by Dr Daniel Jenny (Partner) and Florian Jung (Senior Associate) provided comprehensive legal advice to the seller on the transaction. The team also included David Hürlimann (Partner, Tax), Christian Gersbach (Partner, Employment), Rafael Gruber (Trainee, Corporate/M&A) and Nadine Anwander (Trainee, Corporate/M&A). CMS SwitzerlandDr Daniel Jenny (Partner; Corporate/M&A)Florian Jung (Senior Associate; Corporate/M&A)David Hürlimann (Partner; Tax)Christian Gersbach (Partner; Em­ploy­ment)Ra­fael Gruber (Trainee; Corporate/M&A)Nadine Anwander (Trainee; Corporate/M&A)

CymbiQ Group AG, a portfolio company of the German private equity investor capiton, has sold Aspectra AG to the Convotis Group. Aspectra is a Zurich-based hosting and managed services provider. With the sale of Aspectra AG, the CymbiQ Group strengthens its focus on its strategic core areas with the aim of being the leading provider of premium consulting, services and managed services in the cyber security sector. With around 1000 employees, the Convotis Group, based in Germany, focuses on three areas: Business IT, Platforms and Managed Services. With the acquisition of Aspectra, the Convotis Group is expanding its expertise in hosting and the management of busi­ness-crit­ic­al IT systems. A CMS team led by partner Dr. Daniel Jenny and senior associate Florian Jung provided comprehensive legal advice to the seller. The team also consisted of Mark Cagienard (Partner; Tax) and Miryam Meile (Senior Associate; Employment). CMS SwitzerlandDr Daniel Jenny (Partner; Corporate/M&A)Florian Jung (Senior Associate; Corporate/M&A)Mark Cagienard (Partner; Tax)Miryam Meile (Senior Associate; Employment)

Zurich, May 2024 | ISS Facility Services AG acquires gammaRenax AG. gammaRenax is an accomplished quality provider of integral facility services with 1,800 employees at 16 offices spread across all regions of Switzerland. Versatility, flexibility and customer focus are key characteristics of the owner-managed company's understanding of service. With a portfolio of over 1,600 properties, gammaRenax is one of the most important facility services providers in Switzerland. With this acquisition, ISS seeks to strengthen its position as leading provider of comprehensive facility management services in Switzerland. There are synergies in the customer base and new competencies in the areas of hotel services and hygiene management for pools and wellness areas. With the FM Academy, gammaRenax also has profound expertise in training and further education in areas such as hygiene management, property maintenance and building services. These specialisations will complement the services offered by ISS Switzerland and provide the customers of both companies with an extended range of high-quality services. The seller, Severin Gallo, will join the board of ISS Facility Services AG. ISS Switzerland is the leading provider for workplace experience and facility management. ISS offers intelligent and scalable solutions that contribute to better business performance and make life easier, more productive and more enjoyable - developed to high standards and implemented responsibly by dedicated people. ISS employs around 12,500 people in Switzerland and 350,000 worldwide in over 30 countries.A team of CMS led by Dr Daniel Jenny has advised ISS on all legal aspects of this transaction. The further consisted of Dr Ferdinand Blezinger, Florian Jung, Christian Gersbach, Miryam Meile, Dr Dirk Spacek, Julia Nitschke and Helena Loretan. CMS Switzer­land­Daniel Jenny, Partner, Corporate / M&ADr Ferdinand Blezinger, Senior Associate, Corporate / M&A         Florian Jung, Senior Associate, Corporate / M&A    Christian Gersbach, Partner, Employment Dr Miryam Meile, Senior Associate, EmploymentDr Dirk Spacek, Partner, IP/ITJulia Nitschke , Associate, IP/ITHelena Loretan, Associate, Real estate  

Once again, CMS distinguishes itself as a leader in Switzerland's legal landscape, according to the "Top Law Firm" rankings from the Swiss business magazines BIL­ANZ, the Han­delszei­tung and magazine PME. Across 31 distinct practice areas, CMS von Erlach Partners (CMS Switzerland) has solidified its position among the elite, securing top 25 rankings in an impressive 25 practice areas. This reaffirms our standing as a leading full-service law firm in Switzerland. 

Zurich, March 2024 | Vista Klinik Holding AG, domiciled in Binningen (Switzerland), integrated into its network Augenzentrum Muttenz-Pratteln GmbH, a renowned provider of ophthalmological services in Baselland. The eye centre operates a total of three ultra-modern sites in the municipalities of Muttenz and Pratteln with first-class medical equipment, including state-of-the-art surgery facilities (focused on intravitreal injections). Founded over 30 years ago, Vista Augenpraxen & Kliniken has become a leading centre of excellence for ophthalmology in Switzerland. With its numerous locations, Vista has a broad network of eye clinics and eye practices. At all sites, specialised ophthalmologists offer all treatments and surgical interventions relating to the eye. In this way, Vista guarantees comprehensive and lifelong care for its patients. Forward-looking research activities and the continuous training of all employees ensure quality and sustainability at all sites. A team of CMS Switzerland, led by Stefan Brunnschweiler and Franziska Hammer, advised Vista Augenpraxen & Kliniken on all legal matters of the transaction. CMS Switzer­land­Stefan Brunnschweiler, Partner, Corporate / M&AFranziska Hammer, Counsel, Corporate / M&A          Christoph Willi, Partner, Life Science & HealthcareMiryam Meile, Associate, EmploymentRafael Gruber, Attorney Trainee

Zurich, March 2024 | An international CMS team under the lead of Stefan Brunnschweiler and Florian Jung provided comprehensive advice to Ypsomed (SIX: YPSN) on all legal aspects regarding the sale of its pen needle and blood glucose monitoring systems (BGMs) businesses to Medical Technology and Devices S.p.A. (MTD). Ypsomed is supporting a reliable transition to ensure the supply of pen needles to people around the globe who inject insulin and other hormones. During a transition period, Ypsomed will produce pen needles as a contract manufacturer and provide certain services to facilitate a seamless transfer. The production equipment will be gradually moved to the MTD sites by mid-2025. The business with pen needles and BGMs to be transferred to MTD accounted for sales of CHF 52 million in FY 2022/23 and CHF 18 million in the first half of FY 2023/24. The closing of the transaction and thus the transfer of the business with pen needles and blood glucose monitoring systems is expected in summer 2024, after which the transition will begin, and is subject to customary respectively regulatory conditions. Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company will celebrate its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals as well as under Ypsomed Delivery Systems in busi­ness-to-busi­ness operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries, and distribution partners. Ypsomed has over 2,200 employees worldwide. CMS ZurichStefan Brunnschweiler, LL.M., Managing Partner, Head Corporate/M&AFlorian Jung, LL.M., Senior Associate, Corporate/M&ASamuel Felix Gang, LL.M., Senior Associate, Corporate/M&AAnna Mast, Associate, Corporate/M&AAlexander Salamon, Attorney Trainee, Corporate/M&AMarquard Christen, LL.M., MAS, Partner, Com­pet­i­tion­Sophia Rovelli, Attorney Trainee, Com­pet­i­tion­Nad­ine Anwander, Attorney Trainee, CompetitionDr Matthias Kuert, LL.M., Partner, Capital MarketsMark Cagienard, LL.M. VAT, Partner, TaxChristian Gersbach, LL.M., Partner, EmploymentDirk Spacek, LL.M., Partner, IT/IPCMS ParisAlexandra Rohmert, Partner, Corporate/M&AVincent Desbenoit, Associate, Corporate/M&ACaroline Froger-Michon, Partner, Em­ploy­ment­Ca­mille Baumgarten, Associate, Em­ploy­ment­Aliénor Fevre, Counsel, CommercialManon Fleury, Associate, Com­mer­cialJean-Hugues de la Berge, Partner, TaxWilliam Hamon, Partner, TaxCMS FrankfurtDr Heike Wagner, Partner, Corporate/M&ADr Tobias Kilian, Of Counsel, Corporate/M&ADr Reiner Thieme, Associate, Corporate/M&ACMS HamburgDr Heike Wagner, Partner, Corporate/M&A

This year CMS Switzerland has been recommended by The Legal 500 in 21 categories in the European, Middle Eastern and African (EMEA) edi­tion. In addition, 6 of our lawyers are recognized individually for their expertise as "Leading Individuals" or "Next Generation Partner" in the areas of Competition, Insolvency & Corporate Recovery, Insurance, Public Law, Real Estate & Construction and TMT.